[{"orgOrder":0,"company":"Phoenicia BioScience","sponsor":"National Heart, Lung, and Blood Institute","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"LEBANON","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Benserazide Hydrochloride","moa":"DOPA decarboxylase","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Phoenicia BioScience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Phoenicia BioScience \/ National Heart, Lung, and Blood Institute","highestDevelopmentStatusID":"7","companyTruncated":"Phoenicia BioScience \/ National Heart, Lung, and Blood Institute"}]

Find Clinical Drug Pipeline Developments & Deals for Benserazide Hydrochloride

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Phoenicia BioScience

                          Country arrow
                          Organic Process R&D
                          Not Confirmed

                          Phoenicia BioScience

                          Country arrow
                          Organic Process R&D
                          Not Confirmed

                          Details : Benserazide is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of beta-Thalassemia.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 16, 2020

                          Lead Product(s) : Benserazide Hydrochloride

                          Therapeutic Area : Rare Diseases and Disorders

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : National Heart, Lung, and Blood Institute

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank